Friedhelm Blobel, Ph.D.
Friedhelm Blobel, Ph.D., has served as our President, Chief Executive Officer and a Director since June 2006. From July 2000 to 2006, Dr. Blobel was President, Chief Executive Officer and a Director of Gryphon Therapeutics, Inc., a South San Francisco-based biopharmaceutical company. Prior to joining Gryphon Therapeutics in July 2000, Dr. Blobel spent more than two decades as an executive with the Hoechst Group and the Boehringer Mannheim Group, including responsibilities in the areas of diabetes and in vitro diagnostics. His roles at these companies included Group President of several product divisions, Chief Technology Officer and General Manager in Tokyo, Japan of a marketing and sales joint venture between Boehringer and Yamanouchi Pharmaceuticals (now Astellas Pharma, Inc.), Senior Vice President of Research and Development Diabetes and Patient Care in Mannheim, Germany as well as in Indianapolis, Indiana. Dr. Blobel earned his doctorate degree (“Dr.rer.nat.”; a Ph.D. equivalent) with a dissertation in Biochemistry and Microbiology from the University of Hohenheim, Germany and holds an advanced degree in Chemistry from the University of Stuttgart, Germany.
Hong Zhao joined SciClone as Chief Executive Officer, China Operations, in March 2013. Mr. Zhao joins SciClone from Simcere Pharmaceutical Group, where he served as Executive Vice President, responsible for all business operations, including leading a sizeable sales team and managing multiple business units, and had direct reporting responsibility for medical affairs, market access, marketing and sales operations, training and personnel development. Prior to Simcere, he held positions of increasing seniority at Novartis China, from Regional Sales Manager, National Sales Director, Vice President, Senior Vice President of Novartis Greater China and General Manager of Novartis Shanghai. Mr. Zhao also served with Xi’an Janssen Pharmaceutical, where he rose quickly from Medical Representative to District Sales Manager. Earlier in his career he served as a lecturer and tutor at Nanjing Medical College. Mr. Zhao earned a Bachelor of Medicine degree from Nanjing Medical College and an Executive Masters of Business Administration degree from China European International Business School (CEIBS) in Shanghai.
Wilson W. Cheung
Wilson W. Cheung has served as our Chief Financial Officer and Senior Vice President, Finance since July, 2013. Mr. Cheung is an experienced senior financial and international accounting executive with broad experience spanning financial management, SEC and SOX 404 financial reporting for publicly traded international companies, as well as corporate governance and compliance, operations management, corporate development and investor relations. Mr. Cheung served most recently as Chief Compliance Officer, Asia Pacific of Velti plc, a global mobile marketing and advertising software-as-a-service provider, and previously as Chief Financial Officer, where he took the company public on its Nasdaq IPO, raised over $400 million in equity and debt and oversaw global finance and accounting functions and investor relations. Prior to Velti, Mr. Cheung was Chief Financial Officer and Corporate Secretary at AXT, Inc., a California-based, publicly traded manufacturer of high performance semiconductor substrates, with a major presence in China, where he led the finance and operations teams. Mr. Cheung previously held senior financial positions in telecommunications company InterWAVE Communications International Ltd. (now Alvarion, Ltd), and at Yahoo!, Deloitte, where he advised US companies operating in China, and at KPMG in their Los Angeles, Hong Kong and Beijing offices. Mr. Cheung holds a B.A. from the University of California, Los Angeles (UCLA), and is a Certified Director of Corporate Governance from UCLA’s Executive Program. He is a California Certified Public Accountant (inactive), and speaks English, Cantonese and Mandarin.
Charles Meng joined SciClone as General Counsel and Vice President of Compliance in February 2014. Mr. Meng has more than 20 years of experience in compliance and legal affairs spanning multinational companies in diverse industries. He has practiced law and directed compliance programs in both the US and China. He joins SciClone from Novartis Group, Beijing, where he was General Legal Counsel and Chief Compliance Officer for the pharmaceutical division, and also had responsibility for legal and compliance affairs of other divisions or business units of Novartis China, such as the animal health and vaccine divisions, as well as R&D. Prior to Novartis, Mr. Meng served as Chief Legal Officer of China Bluestar in Beijing, a state-owned chemical company. Previously, he held the position of Legal Director, Greater China Region with AMD (China) Ltd. Earlier in his career he held various positions in legal affairs, including with Motorola (China) Electronics Ltd., Electra Air Conditioning (Shenzhen) Co., Ltd., Allen & Overy, City University of Hong Kong, City Attorneys’ Office (US) and the Ministry of Foreign Affairs in Beijing. Mr. Meng earned his LL.B. from Foreign Affairs College in Beijing, his LL.M from the Faculty of Law, Edinburgh University, Scotland, UK, and his J.D. from the College of Law, Ohio State University.
Min Yin has served as our Vice President, Internal Audit since October 2011. Prior to joining SciClone, she served as Finance Director at Leica Microsystems China. From 2009 to 2010 Ms. Yin was with Beijing Novartis Pharma LTD and served as Senior Director, Finance & Commercial, Oncology. Ms. Yin also held Finance Director positions with Boston Scientific International Medical Trading Corporation from 2004 to 2009 and Valmont Industries, a manufacturer of steel structured poles for lighting, from 1996 to 2004. Ms. Yin holds a Bachelors of Business Administration from the University of Nebraska at Omaha, and a Masters of Business Administration from the University of New Jersey and is a Certified Public Accountant.
Raymond A. Low
Raymond A. Low joined SciClone as Vice President, Finance and Controller in October 2013. He was formerly Chief Financial Officer at AXT. Formerly, Mr. Low was Corporate Controller of Therasense, Inc. (now Abbott Laboratories). Mr. Low also served as Corporate Controller of RStar Networks Inc., and as Director of Accounting for AT&T. Mr. Low also worked in public accounting with BDO Seidman in San Francisco, and with Deloitte & Touche in South Africa. Mr. Low is a California certified public accountant, and a member of the California Society of CPAs. He is a past member of the Chartered Institute of Management Accountants in the United Kingdom. Mr. Low has an M.B.A. degree from Chadwick University, Alabama, a Bachelor of Accounting Science Honors degree from the University of South Africa, and a Bachelor of Commerce degree from Rhodes University, South Africa.
Lan Xie joined SciClone as Vice President, Finance and Chief Financial Officer, China Operations in 2012. Ms. Xie has more than 18 years of experience in financial management and operations in the US and China. Her professional experience includes: Shangpharma Corp. where she was VP Finance and IR, and successfully listed the company in the US; PriceWaterhouseCoopers in Shanghai, where she was senior manager, transaction services; Deloitte & Touche in NY, where she was manager, mergers and acquisitions; Reuters Incorporated, where she was finance manager, special projects; and PriceWaterhouseCoopers in Boston where she was a senior associate. She is a US CPA and received her MBA from INSEAD, Singapore/France.
Robert King, Ph.D.
Robert King joined SciClone as Vice President, Product Development and Manufacturing in 2011. At SciClone, Dr. King oversees the manufacturing of active pharmaceutical ingredients (API), drug products, quality control and directs activities related to chemistry, manufacturing and controls (CMC). Robert has over 20 years of experience in the pharmaceutical industry, most recently as Vice President, Product Development and Manufacturing at Bayhill Therapeutics. Prior to Bayhill, Dr. King was VP, Product Development and Manufacturing at Rinat Neuroscience Corporation (a division of Pfizer Global R & D). Dr. King has also worked at a number of biotechnology companies, including Millennium Pharmaceuticals, COR Therapeutics, Inc., Scios and Molecular Devices Corporation. Dr. King has a PhD in Chemical Engineering from UC Berkeley and a BS in Chemical Engineering from the University of Washington.